Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 1, January-February, p. 5–10

doi: 10.17219/acem/22636

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Extending Myringotomy Patency with Topical Everolimus in Rats

Sevtap Akbulut1,A,B,C,D,E,F, Hande Altintas2,A,B,C,D,E,F, Derya Berk1,B,D,E,F, Nagehan Ozdemir3,A,C,D,F

1 Department of Otolaryngology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey

2 Department of Otolaryngology, Acibadem Hospital, Istanbul, Turkey

3 Department of Pathology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey


Background. Everolimus is an immunosuppressant agent that has antiproliferative properties and negative effects on wound healing. The effect of everolimus use to delay the closure time of myringotomy is not known.
Objectives. The aim of the study was to evaluate the impact of topical everolimus on myringotomy patency and to investigate its histopathologic effects on the tympanic membrane.
Material and Methods. Twenty Sprague-Dawley rats were bilaterally myringotomized with a myringotomy knife. Gelfoam soaked in 0.05% everolimus in a microemulsion formulation was applied to the right myringotomy site of the rats for 10 min (the everolimus group). The myringotomy sites of the left ears were treated with sterile saline topically (the control group). The tympanic membranes were routinely examined otomicroscopically every other day for 31 days. The membranes were then harvested and evaluated histologically after 31 days.
Results. All tympanic membranes were closed by the 15th day in the control group, while in the everolimus group the myringotomy remained open in five rats (25%) on day 31. The mean durations of myringotomy patency in the everolimus group and control group were 20.90 ± 7.85 and 10.10 ± 3.14 days, respectively. The difference was found to be statistically significant (p < 0.01). In the histopathological examination of the tympanic membranes, there was less fibrosis and less inflammation in the everolimus group than in the control group (p < 0.01).
Conclusions. Topical everolimus application is effective in extending myringotomy patency in rat tympanic membranes. Inflammatory reactions and fibrosis in the lamina propria were observed to be significantly less when topical everolimus was used.

Key words

myringotomy, tympanic membrane, everolimus, histopathology, rat

References (30)

  1. Kozak LJ, Owings MF, Hall MJ: National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 2005, 158, 1–199.
  2. Handler SD: Current indications for tympanostomy tubes. Am J Otolaryngol 1994, 15, 103–108.
  3. Luxford WM, Sheehy JL: Myringotomy and ventilation tubes: A report of 1,568 ears. Laryngoscope 1982, 92, 1293–1297.
  4. Clements KS, Vrabec JT, Mader JT: Complication of tympanostomy tubes inserted for facilitation of hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg 1998, 124, 278–280.
  5. Nedzelski JM, Bryce GE, Pfleiderer AG: Treatment of Meniere’s disease with topical gentamicin: A preliminary report. J Otolaryngol 1992, 21, 95–101.
  6. Weigel MT, Parker MY, Goldsmith MM, Postma DS, Pillsbury HC: A prospective randomized study of four commonly used tympanostomy tubes. Laryngoscope 1989, 99, 252–256.
  7. Derkay CS, Carron JD, Wiatrak BJ, Choi SS, Jones JE: Postsurgical follow-up of children with tympanostomy tubes: results of the American Academy of Otolaryngology-Head Neck Surgery Pediatric Otolaryngology Committee National Survey. Otolaryngol Head Neck Surg 2000, 122, 313–318.
  8. Estrem SA, Batra PS: Preventing myringotomy closure with topical mitomycin C in rats. Otolaryngol Head Neck Surg 1999, 120, 794–798.
  9. Estrem SA, Baker TJ: Preapplication of mitomycin C for enhanced patency of myringotomy. Otolaryngol Head Neck Surg 2000, 122, 346–348.
  10. Jassir D, Buchman CA, Gomez-Marin O: Safety and efficacy of topical mitomycin C in myringotomy patency. Otolaryngol Head Neck Surg 2001, 124, 368–373.
  11. Cakir BO, Dadas B, Basak T, Cinar U, Ozdogan HC, Uslu B, Turgut S: Effect of topical 5-fluorouracil on closure time of myringotomies created by a radiofrquency surgical unit in guinea pigs. Otol Neurotol 2002, 23, 146–151.
  12. Cincik H, Gungor A, Cekin E, Saglam O, Yildirim S, Poyrazoglu E, Candan H: Effects of topical application of mitomycin C and 5-fluorouracil on myringotomy in rats. Otol Neurotol 2005, 26, 351–354.
  13. Ozdemir T, Cincik H, Dogru S, Cekin IE, Ulubil SA, Gungor A: Efficacy of topical halofuginone in myringotomy patency. Eur Arch Otorhinolaryngol 2010, 267, 1701–1704.
  14. Pascual J, Boletis IN, Campisto JM: Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev 2006, 20, 1–18.
  15. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valentine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349, 847–858.
  16. Van der Vliet JA, Willems MC, de Man BM, Lomme RM, Hendriks T: Everolimus interferes with healing of experimental intestinal anastomoses. Transplantation 2006, 82, 1477–1483.
  17. Kuper MA, Scholzl N, Traub F, Mayer P, Weinreich J, Coerper S, Steurer W, Konigsrainer A, Beckert S: Everolimus interferes with the inflammatory phase of healing in experimental colonic anastomoses. J Surg Res 2011, 167, 158–165.
  18. Willems MC, van der Vliet JA, de Man BM, van der Laak JA, Lomme RM, Hendriks T: Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Rep Regen 2010, 18, 98–104.
  19. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ: Sixand twelve-month results from first human experience using everolimus-eluting stents bioabsorbable polymer. Circulation 2004, 109, 2168–2171.
  20. Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Muller R, Storger H, Hauptmann KE, Grube E: Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006, 98, 464–469.
  21. Akbulut S, Altintas H, Berk D, Sezen OS, Barisik NO: Everolimus-coated tympanostomy tube on rat tympanic membrane. Int J Ped Otorhinolaryngol 2013, 77, 1147–1151.
  22. Sehgal SN: Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995, 17, 660–665.
  23. Nashan B: The role of certican (everolimus, RAD) in the many pathways of chronic rejection. Transplant Proc 2001, 33, 3215–3220.
  24. Nair RV, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R, Morris RE: Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997, 29, 614–615.
  25. Simler NR, Howell DCJ, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, Chambers RC, Egan JJ: The rapamycin analogue SDZ RAD attenuates belomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002, 19, 1124–1127.
  26. Ekici Y, Emiroglu R, Ozdemir H, Aldemir D, Karakayali H, Haberal M: Effect of rapamycine on wound healing: an experimental study. Transplant Proc 2007, 39, 1201–1203.
  27. Li XQ, Buch G, Otasevic L, Schlickeiser S, Bertelmann E, Pleyer U: Prolongation of corneal allograft survival by topical application of everolimus in experimental keratoplasty. Ophthalmic Res 2008, 40, 309–314.
  28. Zohlnhofer D, Nuhrenberg TG, Neumann FJ, Richter T, May AE, Schmidt R, Denker K, Clauss MA, Schomig A, Baeuerle PA: Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammmatory properties. Mol Pharmacol 2004, 65, 880–889.
  29. Ragab SM: The effect of radiofrequency and mitomycin C on the closure rate of human tympanostomy. Otol Neurotol 2005, 26, 355–360.
  30. Kanemaru S, Nakamura T, Yamashita M, Magrfov A, Omori K: Ito J. 5-Fluorouracil ointment for the treatment of otitis media with effusion. Laryngoscope 2007, 117, 215–219.